Chronic Myeloid Leukemia

The efficacy of LDAC plus quizartinib versus LDAC alone in patients aged ≥60 years unable to undergo intensive therapy was assessed. Although addition of quizartinib to LDAC did not result in improved survival for the study population, it did improve survival for the FLT3- ITD patient subgroup. Read More ›

To our knowledge, cases of successful treatment of chronic myeloid leukemia (CML) with low-dose nilotinib (Tasigna) have not been reported. The following case represents our experience with a patient with CML who achieved good response to nilotinib therapy. Read More ›


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: